Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis.
Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Bahonar A, Nakhaee Z, Entezari M, Beig Goharrizi MAS, Salimimoghadam S, Ren J, Nabavi N, Rashidi M, Dehkhoda F, Taheriazam A, Tan SC, Hushmandi K. Sadrkhanloo M, et al. Among authors: nabavi n. Pathol Res Pract. 2023 Nov;251:154902. doi: 10.1016/j.prp.2023.154902. Epub 2023 Oct 21. Pathol Res Pract. 2023. PMID: 37922723 Review.
Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents.
Hashemi M, Mirdamadi MSA, Talebi Y, Khaniabad N, Banaei G, Daneii P, Gholami S, Ghorbani A, Tavakolpournegari A, Farsani ZM, Zarrabi A, Nabavi N, Zandieh MA, Rashidi M, Taheriazam A, Entezari M, Khan H. Hashemi M, et al. Among authors: nabavi n. Pharmacol Res. 2023 Jan;187:106568. doi: 10.1016/j.phrs.2022.106568. Epub 2022 Nov 21. Pharmacol Res. 2023. PMID: 36423787 Free article. Review.
Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies.
Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, Babaei R, Sadi FH, Rajabi R, Abkenar ZO, Rezaei S, Ren J, Nabavi N, Khorrami R, Rashidi M, Hushmandi K, Entezari M, Taheriazam A. Hashemi M, et al. Among authors: nabavi n. Biomed Pharmacother. 2023 Apr;160:114392. doi: 10.1016/j.biopha.2023.114392. Epub 2023 Feb 15. Biomed Pharmacother. 2023. PMID: 36804123 Free article. Review.
Unraveling the function of epithelial-mesenchymal transition (EMT) in colorectal cancer: Metastasis, therapy response, and revisiting molecular pathways.
Sabouni E, Nejad MM, Mojtabavi S, Khoshduz S, Mojtabavi M, Nadafzadeh N, Nikpanjeh N, Mirzaei S, Hashemi M, Aref AR, Khorrami R, Nabavi N, Ertas YN, Salimimoghadam S, Zandieh MA, Rahmanian P, Taheriazam A, Hushmandi K. Sabouni E, et al. Among authors: nabavi n. Biomed Pharmacother. 2023 Apr;160:114395. doi: 10.1016/j.biopha.2023.114395. Epub 2023 Feb 15. Biomed Pharmacother. 2023. PMID: 36804124 Free article. Review.
Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective.
Hashemi M, Zandieh MA, Ziaolhagh S, Mojtabavi S, Sadi FH, Koohpar ZK, Ghanbarirad M, Haghighatfard A, Behroozaghdam M, Khorrami R, Nabavi N, Ren J, Reiter RJ, Salimimoghadam S, Rashidi M, Hushmandi K, Taheriazam A, Entezari M. Hashemi M, et al. Among authors: nabavi n. Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166714. doi: 10.1016/j.bbadis.2023.166714. Epub 2023 Apr 5. Biochim Biophys Acta Mol Basis Dis. 2023. PMID: 37028606 Free article. Review.
Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance.
Hashemi M, Sabouni E, Rahmanian P, Entezari M, Mojtabavi M, Raei B, Zandieh MA, Behroozaghdam M, Mirzaei S, Hushmandi K, Nabavi N, Salimimoghadam S, Ren J, Rashidi M, Raesi R, Taheriazam A, Alexiou A, Papadakis M, Tan SC. Hashemi M, et al. Among authors: nabavi n. Cell Mol Biol Lett. 2023 Apr 21;28(1):33. doi: 10.1186/s11658-023-00438-9. Cell Mol Biol Lett. 2023. PMID: 37085753 Free PMC article. Review.
Chitosan-based nanoscale delivery systems in hepatocellular carcinoma: Versatile bio-platform with theranostic application.
Karimi K, Mojtabavi S, Tehrany PM, Nejad MM, Rezaee A, Mohtashamian S, Hamedi E, Yousefi F, Salmani F, Zandieh MA, Nabavi N, Rabiee N, Ertas YN, Salimimoghadam S, Rashidi M, Rahmanian P, Hushmandi K, Yu W. Karimi K, et al. Among authors: nabavi n. Int J Biol Macromol. 2023 Jul 1;242(Pt 3):124935. doi: 10.1016/j.ijbiomac.2023.124935. Epub 2023 May 23. Int J Biol Macromol. 2023. PMID: 37230442 Review.
STAT3 as a newly emerging target in colorectal cancer therapy: Tumorigenesis, therapy response, and pharmacological/nanoplatform strategies.
Hashemi M, Abbaszadeh S, Rashidi M, Amini N, Talebi Anaraki K, Motahhary M, Khalilipouya E, Harif Nashtifani A, Shafiei S, Ramezani Farani M, Nabavi N, Salimimoghadam S, Aref AR, Raesi R, Taheriazam A, Entezari M, Zha W. Hashemi M, et al. Among authors: nabavi n. Environ Res. 2023 Sep 15;233:116458. doi: 10.1016/j.envres.2023.116458. Epub 2023 Jun 20. Environ Res. 2023. PMID: 37348629 Review.
Biological and therapeutic viewpoints towards role of miR-218 in human cancers: Revisiting molecular interactions and future clinical translations.
Hashemi M, Gholami S, Raesi R, Sarhangi S, Mahmoodieh B, Koohpar ZK, Goharrizi MASB, Behroozaghdam M, Entezari M, Salimimoghadam S, Zha W, Rashidi M, Abdi S, Taheriazam A, Nabavi N. Hashemi M, et al. Among authors: nabavi n. Cell Signal. 2023 Sep;109:110786. doi: 10.1016/j.cellsig.2023.110786. Epub 2023 Jun 27. Cell Signal. 2023. PMID: 37380085
142 results